The high cost of drugs has become a bipartisan discussion among representatives in Washington, DC. Both the Trump and Biden administrations have taken actions to reduce healthcare spending, and particularly have focused on prescription drug spending.
In order to better understand these recent policies and their expected impact on US healthcare payers and manufacturers, Two Labs conducted a panel event with Medical Directors and Pharmacy Directors from managed care organizations (MCOs) and pharmacy benefit managers (PBMs). In addition, a policy expert with experience at a large national health plan, as well as CMS participated in the discussion.
To download the paper and read more, fill out the form below.
Download the white paper